Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanda Reports Strong Phase III Data For Sleep Disorder Candidate In Chronic Insomnia

This article was originally published in The Pink Sheet Daily

Executive Summary

VEC-162 also being tested in transient insomnia, circadian rhythm sleep disorders and mood disorders.

You may also be interested in...



“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future

FDA requests additional Phase III comparative study and safety data for iloperidone.

“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future

FDA requests additional Phase III comparative study and safety data for iloperidone.

Actelion Accepts Payoff Risk In GSK Deal For Phase III Insomnia Drug

Almorexant deal guarantees Swiss biotech $148 million, but another $409 million rides on approval, and the $2.7 billion for new indications is a bio-bucks poster number.

Related Content

Topics

UsernamePublicRestriction

Register

PS067992

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel